Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome
3
Issued Date
2022-05-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-85128737793
Journal Title
Journal of Clinical Medicine
Volume
11
Issue
9
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.11 No.9 (2022)
Suggested Citation
Boonchai P., Kositamongkol C., Jitrukthai S., Phothirat S., Mepramoon E., Nimitpunya P., Srivanichakorn W., Chaisathaphol T., Washirasaksiri C., Auesomwang C., Sitasuwan T., Tinmanee R., Sayabovorn N., Charatcharoenwitthaya P., Phisalprapa P. Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. Journal of Clinical Medicine Vol.11 No.9 (2022). doi:10.3390/jcm11092445 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87320
Title
Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome
Author's Affiliation
Other Contributor(s)
Abstract
This study investigated differences in the clinical data and prevalence of lean and non-lean patients with non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS). Data on patients with MetS who had results of ultrasonography or transient elastography were collected from a Thai university hospital database. Patients with exclusion criteria for NAFLD diagnosis were excluded. Patients’ clinical characteristic and the performances of three non-invasive scoring systems (fatty liver index [FLI], fibrosis-4 [FIB-4] index, and NAFLD fibrosis score [NFS]) were evalu-ated. The 743 subjects were classified into two groups: lean MetS (131 patients) and non-lean MetS (612 patients). The NAFLD prevalence in the non-lean group (62.6%) was higher than that in the lean group (31.3%). The age-adjusted odds ratio was 3.43. Advanced fibrosis was detected in 7.6% of lean patients and 10.8% of non-lean patients. FLI was not sensitive enough to detect NAFLD in the lean group at a high cutoff, but it performed acceptably at a low cutoff. FIB-4 performed better than NFS in determining advanced fibrosis. NAFLD was more common in non-lean than lean pa-tients. Lean patients with MetS had a relatively higher risk of NAFLD than the general population. FLI and FIB-4 index performed acceptably in both groups.